Summary
The irony of the timing could not have been more acute. On the second and final day of the BioEquity Europe conference which aimed to showcase British biotech to the world it was announced that one of the big hopes of the sector was being sold off.
The sale of the UK sector's flagship company Celltech to UCB of Belgium in a (pounds) 1.5 billion deal was a big setback.See the full content of this document
Extract
Biotech Companies Must Be Given Room to Succeed
It seems that just as a company makes it near the top of the hill to challenge American dominance in the sector, it is picked off from elsewhere.
The Celltech ...See the full content of this document
Sponsored links
